675 related articles for article (PubMed ID: 17640607)
21. Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia.
Gebru-Woldearegai T; Hailu A; Grobusch MP; Kun JF
Am J Trop Med Hyg; 2005 Dec; 73(6):1131-4. PubMed ID: 16354825
[TBL] [Abstract][Full Text] [Related]
22. Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea.
Mita T; Kaneko A; Hwaihwanje I; Tsukahara T; Takahashi N; Osawa H; Tanabe K; Kobayakawa T; Björkman A
Infect Genet Evol; 2006 Nov; 6(6):447-52. PubMed ID: 16600696
[TBL] [Abstract][Full Text] [Related]
23. [Monitoring the chemoresistance of Plasmodium falciparum malaria in Yopougon (Abidjan): in vivo study of chloroquine sensitivity and evaluation of pyrimethamine resistance following the analysis of point mutation in the dihydrofolate reductase gene].
Djaman AJ; Basco LK; Mazabraud A
Sante; 2002; 12(4):363-7. PubMed ID: 12626289
[TBL] [Abstract][Full Text] [Related]
24. A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa.
Maïga O; Djimdé AA; Hubert V; Renard E; Aubouy A; Kironde F; Nsimba B; Koram K; Doumbo OK; Le Bras J; Clain J
J Infect Dis; 2007 Jul; 196(1):165-72. PubMed ID: 17538897
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
[TBL] [Abstract][Full Text] [Related]
26. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
Bwijo B; Kaneko A; Takechi M; Zungu IL; Moriyama Y; Lum JK; Tsukahara T; Mita T; Takahashi N; Bergqvist Y; Björkman A; Kobayakawa T
Acta Trop; 2003 Mar; 85(3):363-73. PubMed ID: 12659974
[TBL] [Abstract][Full Text] [Related]
27. Treatment of uncomplicated malaria with artesunate plus sulfadoxine-pyrimethamine is failing in Somalia: evidence from therapeutic efficacy studies and Pfdhfr and Pfdhps mutant alleles.
Warsame M; Hassan AM; Barrette A; Jibril AM; Elmi HH; Arale AM; Mohammady HE; Nada RA; Amran JG; Muse A; Yusuf FE; Omar AS
Trop Med Int Health; 2015 Apr; 20(4):510-7. PubMed ID: 25583123
[TBL] [Abstract][Full Text] [Related]
28. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity.
Alifrangis M; Enosse S; Khalil IF; Tarimo DS; Lemnge MM; Thompson R; Bygbjerg IC; Rønn AM
Am J Trop Med Hyg; 2003 Dec; 69(6):601-6. PubMed ID: 14740875
[TBL] [Abstract][Full Text] [Related]
29. Increasing prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets.
Alifrangis M; Lemnge MM; Rønn AM; Segeja MD; Magesa SM; Khalil IF; Bygbjerg IC
Am J Trop Med Hyg; 2003 Sep; 69(3):238-43. PubMed ID: 14628937
[TBL] [Abstract][Full Text] [Related]
30. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.
Plowe CV; Cortese JF; Djimde A; Nwanyanwu OC; Watkins WM; Winstanley PA; Estrada-Franco JG; Mollinedo RE; Avila JC; Cespedes JL; Carter D; Doumbo OK
J Infect Dis; 1997 Dec; 176(6):1590-6. PubMed ID: 9395372
[TBL] [Abstract][Full Text] [Related]
31. Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes.
Méndez F; Herrera S; Murrain B; Gutiérrez A; Moreno LA; Manzano M; Muñoz A; Plowe CV
Am J Trop Med Hyg; 2007 Sep; 77(3):438-43. PubMed ID: 17827356
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in East Timor.
Burns M; Baker J; Auliff AM; Gatton ML; Edstein MD; Cheng Q
Am J Trop Med Hyg; 2006 Mar; 74(3):361-6. PubMed ID: 16525092
[TBL] [Abstract][Full Text] [Related]
33. A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR.
Toma H; Imada Y; Vannachone B; Miyagi M; Kobayashi J; Uechi G; Pethuvang R; Manivong K; Phompida S; Sato Y
Southeast Asian J Trop Med Public Health; 2005 May; 36(3):602-4. PubMed ID: 16124424
[TBL] [Abstract][Full Text] [Related]
34. Declining trend of Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant alleles after the withdrawal of Sulfadoxine-Pyrimethamine in North Western Ethiopia.
Tessema SK; Kassa M; Kebede A; Mohammed H; Leta GT; Woyessa A; Guma GT; Petros B
PLoS One; 2015; 10(10):e0126943. PubMed ID: 26431464
[TBL] [Abstract][Full Text] [Related]
35. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites.
Nzila AM; Mberu EK; Sulo J; Dayo H; Winstanley PA; Sibley CH; Watkins WM
Antimicrob Agents Chemother; 2000 Apr; 44(4):991-6. PubMed ID: 10722502
[TBL] [Abstract][Full Text] [Related]
36. Source of drug resistant Plasmodium falciparum in a potential malaria elimination site in Saudi Arabia.
Al-Farsi HM; Al-Hashami ZS; Bin Dajem SM; Al-Sheikh AA; Al-Qahtani A; Beja-Pereira A; Idris MA; Babiker HA
Infect Genet Evol; 2012 Aug; 12(6):1253-9. PubMed ID: 22709478
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of sulfadoxine-pyrimethamine resistance-associated mutations in dhfr and dhps genes of Plasmodium falciparum three years after SP withdrawal in Bahir Dar, Northwest Ethiopia.
Hailemeskel E; Kassa M; Taddesse G; Mohammed H; Woyessa A; Tasew G; Sleshi M; Kebede A; Petros B
Acta Trop; 2013 Dec; 128(3):636-41. PubMed ID: 24055717
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations.
Kakar Q; Sheikh S; Ahmed I; Khan MA; Jamil M; ElMohammady H; Warsame M
Acta Trop; 2016 Dec; 164():17-22. PubMed ID: 27515812
[TBL] [Abstract][Full Text] [Related]
39. Ordered accumulation of mutations conferring resistance to sulfadoxine-pyrimethamine in the Plasmodium falciparum parasite.
Mita T; Ohashi J; Venkatesan M; Marma AS; Nakamura M; Plowe CV; Tanabe K
J Infect Dis; 2014 Jan; 209(1):130-9. PubMed ID: 23922363
[TBL] [Abstract][Full Text] [Related]
40. Molecular epidemiology of malaria in Cameroon. XXX. sequence analysis of Plasmodium falciparum ATPase 6, dihydrofolate reductase, and dihydropteroate synthase resistance markers in clinical isolates from children treated with an artesunate-sulfadoxine-pyrimethamine combination.
Menemedengue V; Sahnouni K; Basco L; Tahar R
Am J Trop Med Hyg; 2011 Jul; 85(1):22-5. PubMed ID: 21734119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
